The Claim

In adults with essential hypertension, adding a third antihypertensive agent to chlorthalidone and metoprolol increases the proportion achieving diastolic blood pressure control (<95 mmHg) from 79.5% to 61.8%, suggesting diminishing returns and potential over-treatment in a subset of patients.

Source: Chlorthalidone Alone or in Fixed Combination with Slow-Release Metoprolol in the Management of Arterial Hypertension: A Long-Term Study of 545 Patients

What the research says

Not yet evaluated

We are still looking at what the research says.

Supports
0score
Challenges
0score

These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.

Quantitative
1 study reviewed
In plain English

Adding a third blood pressure medication to two already taken by adults with essential hypertension increases the proportion reaching diastolic blood pressure control from 79.5% to 61.8%, indicating reduced benefit and possible unnecessary treatment in some individuals.

See the scientific wording

In adults with essential hypertension, adding a third antihypertensive agent to chlorthalidone and metoprolol increases the proportion achieving diastolic blood pressure control (<95 mmHg) from 79.5% to 61.8%, suggesting diminishing returns and potential over-treatment in a subset of patients.

Why this might work

When two blood pressure-lowering drugs are already working, adding a third one does not push blood pressure lower in many people because the blood vessels have already relaxed as much as they can, and the body's natural systems start resisting further drops by tightening blood vessels or holding onto more salt and water.

Suggested mechanismbased on 1 study

What the research says

1 study

  1. Study: Chlorthalidone Alone or in Fixed Combination with Slow-Release Metoprolol in the Management of Arterial Hypertension: A Long-Term Study of 545 Patients

    The study observed that adding a third drug to the combination therapy resulted in a lower response rate (61.8%) than the combination alone (79.5%). This counterintuitive result likely reflects that the third drug was added to patients with more resistant hypertension, making it a marker of severity rather than a cause of reduced efficacy.

Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies

Fit Body Science verdict — we translate health claims into clear verdicts backed by peer-reviewed research.

Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.